DE68912419D1 - Verwendung von Uridin zur Behandlung nervöser Störungen. - Google Patents

Verwendung von Uridin zur Behandlung nervöser Störungen.

Info

Publication number
DE68912419D1
DE68912419D1 DE89830264T DE68912419T DE68912419D1 DE 68912419 D1 DE68912419 D1 DE 68912419D1 DE 89830264 T DE89830264 T DE 89830264T DE 68912419 T DE68912419 T DE 68912419T DE 68912419 D1 DE68912419 D1 DE 68912419D1
Authority
DE
Germany
Prior art keywords
uridine
nervous disorders
treat nervous
treat
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE89830264T
Other languages
English (en)
Other versions
DE68912419T2 (de
Inventor
Luca Giovanna De
Stazio Giovanni Di Stazio G Di
Mario Materazzi
Vincenzo Politi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Polifarma SpA
Original Assignee
Polifarma SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polifarma SpA filed Critical Polifarma SpA
Publication of DE68912419D1 publication Critical patent/DE68912419D1/de
Application granted granted Critical
Publication of DE68912419T2 publication Critical patent/DE68912419T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE68912419T 1988-06-21 1989-06-14 Verwendung von Uridin zur Behandlung nervöser Störungen. Expired - Fee Related DE68912419T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT48118/88A IT1219667B (it) 1988-06-21 1988-06-21 Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico

Publications (2)

Publication Number Publication Date
DE68912419D1 true DE68912419D1 (de) 1994-03-03
DE68912419T2 DE68912419T2 (de) 1994-08-04

Family

ID=11264638

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68912419T Expired - Fee Related DE68912419T2 (de) 1988-06-21 1989-06-14 Verwendung von Uridin zur Behandlung nervöser Störungen.

Country Status (8)

Country Link
US (1) US4960759A (de)
EP (1) EP0348360B1 (de)
JP (1) JPH0623109B2 (de)
KR (1) KR900000092A (de)
AT (1) ATE100322T1 (de)
CA (1) CA1327003C (de)
DE (1) DE68912419T2 (de)
IT (1) IT1219667B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2634374B1 (fr) * 1988-07-19 1993-10-15 Laboratoires Serobiologiques Agents photoprotecteurs, cytophotoprotecteurs cutanes ayant une activite photoprotectrice des cellules constitutives, fonctionnelles de la peau, en particulier des cellules de langerhans, a base de composes nucleiques : nucleoprotides, ribonucleotides et desoxyribonucleotides, ribonucleosides et desoxyribonucleosides, compositions cosmetiques ou dermo-pharmaceutiques contenant un tel agent ainsi que des nouveaux composes en soi
WO1994026280A1 (en) * 1993-05-19 1994-11-24 Korea Green Cross Corporation Remedy for arthritis containing uridine as active ingredient
IT1290781B1 (it) * 1996-05-28 1998-12-10 Polifarma Spa Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
US5962459A (en) * 1996-05-28 1999-10-05 Polifarma S.P.A. Therapeutic active agent for treatment of neuron degenerative diseases
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US8314064B2 (en) 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
US8518882B2 (en) 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
US20050203053A1 (en) * 1999-07-30 2005-09-15 Wurtman Richard J. Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
DE69941586D1 (de) 1998-07-31 2009-12-03 Massachusetts Inst Technology Verwendung von Uridin in Kombination mit Cholin zur Behandlung von Gedächtnisstörungen
US20060069061A1 (en) * 1998-07-31 2006-03-30 Dick Wurtman Compositions containing uridine and choline, and methods utilizing same
US8143234B2 (en) 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US7915233B1 (en) 1998-08-31 2011-03-29 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
US7807654B2 (en) 1998-08-31 2010-10-05 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
CA2362925C (en) 1999-02-23 2011-04-12 Regents Of The University Of California Methods of treatment of mitochondrial disorders
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
US6727231B1 (en) 2000-10-12 2004-04-27 Repligen Corporation Uridine therapy for patients with elevated purine levels
AUPR951101A0 (en) 2001-12-13 2002-01-24 Centre For Molecular Biology And Medicine Method of treatment
CA2542023A1 (en) * 2003-10-08 2005-09-22 The Mclean Hospital Corporation Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
CA2566612C (en) * 2004-05-13 2015-06-30 Massachusetts Institute Of Technology Uridine effects on dopamine release
EP2407167A3 (de) * 2005-11-24 2012-06-27 National University Corporation Hokkaido University Therapeutikum für neurodegenerative Erkrankungen
EP1897937A1 (de) * 2006-09-07 2008-03-12 NeuroProgen GmbH Leipzig Verfahren zur Züchtung von neuralen Vorläuferzellen
CN101896119A (zh) 2007-11-02 2010-11-24 麻省理工学院 尿苷饮食添加顺应性方法及其用途
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
EP2459194A4 (de) 2009-07-31 2012-12-19 Clera Inc Zusammensetzungen und verfahren zur behandlung von parkinson

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1178044B (it) * 1984-10-09 1987-09-03 Polifarma Spa Agente attivo farmaceutico per il trattamento di patologie cerebrali a base di uridina
JPH0669953B2 (ja) * 1985-08-16 1994-09-07 日産化学工業株式会社 脳脊髄系神経栄養剤
CA1321994C (en) * 1987-10-28 1993-09-07 Reid Von Borstel Acylated uridine and cytidine and uses thereof

Also Published As

Publication number Publication date
IT8848118A0 (it) 1988-06-21
US4960759A (en) 1990-10-02
JPH0245425A (ja) 1990-02-15
EP0348360A2 (de) 1989-12-27
EP0348360B1 (de) 1994-01-19
IT1219667B (it) 1990-05-24
EP0348360A3 (de) 1991-10-23
ATE100322T1 (de) 1994-02-15
CA1327003C (en) 1994-02-15
KR900000092A (ko) 1990-01-30
DE68912419T2 (de) 1994-08-04
JPH0623109B2 (ja) 1994-03-30

Similar Documents

Publication Publication Date Title
DE68912419D1 (de) Verwendung von Uridin zur Behandlung nervöser Störungen.
DK0431580T3 (da) Substituerede cyclohexanoler med virkning på centralnervesystemet
DE69012591D1 (de) Verwendung von Nikotin zur Herstellung eines Kit zur Behandlung von Krankheitszuständen, die auf eine Nikotinbehandlung ansprechen.
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
ES2078440T3 (es) Compuestos farmaceuticos.
DE10199020I1 (de) Galanthamin oder dessen Analoge zur Behandlung der Alzheimerschen Krankheit
DE69017302D1 (de) Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten.
DE69012261D1 (de) Verwendung von Sertralin zur Behandlung verfrühter Ejakulation.
EP0616032A3 (de) Verbeugende oder therapeutische Mittel für die Alzheimer-Krankheit, eine Siebtest-Methode, und die menschliche Tau-Protein-Kinase.
ES2086666T3 (es) Composiciones de activacion cerebral.
DE69928521D1 (de) Cabergolin und pramipexol zur behandlung von krankheiten des zentralnervensystems, insbesondere parkinsonscher krankheit
DE69822300D1 (de) 3-pyridyl-1-azabicycloalkan-derivate zur behandlung von zns-erkrankungen
ATE147626T1 (de) Verwendung von pirenzepine, telenzepine oder o- methoxy -sila-hexocyclium zur herstellung eines medikaments zur behandlung und regulierung der augenentwicklung
AU560542B2 (en) Pyridazine derivatives which have c.n.s. activity
ATE96999T1 (de) Verwendung von sertralin zur behandlung von abhaengigkeiten von chemischen stoffen.
DE3780542D1 (en) Substituierte hexahydroarylchinolizine.
ATE80998T1 (de) Verwendung von nalmefen zur herstellung eines arzneimittels zur behandlung der schaedigung des zentralnervensystems.
MX9206635A (es) Cicloalquenos y cicloalcanos 1,3-substituidos como agentes del sistema nervioso central.
ATE78160T1 (de) Verwendung von ''naftidrofuryl'' zur behandlung von neuropathien.
MX9302225A (es) Cicloalquenos y cicloalcanos 1,3-substituidos como agentes del sistema nervioso central.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee